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Background: The pharmacokinetics and pharmacodynamics of antidiabetic therapies for patients with
type 2 diabetes are often altered in the context of chronic kidney disease (CKD).
Study Design: Systematic review and meta-analysis.
Setting & Population: Patients with type 2 diabetes and CKD.
Selection Criteria for Studies: 2 reviewers independently screened studies identified through bibliographic
databases (Cochrane Library, PubMed, Embase, International Pharmaceutical Abstracts), clinical trial regis-
tries, and references from pertinent articles and clinical practice guidelines. Eligible studies included ran-
domized controlled trials evaluating incretin-based therapy in adults with type 2 diabetes and estimated
glomerular filtration rates , 60 mL/min/1.73 m2.
Interventions: Incretin-based therapies (dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1
receptor agonists) compared to placebo or active antidiabetic therapies.
Outcomes: Changes in glycated hemoglobin (HbA1c), hypoglycemia, mortality, change in fasting plasma
glucose, cardiovascular events, and end-stage renal disease.
Results:Of 1,619 nonduplicate records screened, 13 studies were included. Compared to placebo, incretin-
based therapies significantly reduced HbA1c levels (n 5 9; weighted mean difference, 20.64; 95% CI, 20.79
to 20.48; I 2 5 43%); however, compared with active comparators, they did not (n 5 4; weighted mean
difference, 20.07; 95% CI, 20.25 to 0.12; I 2 5 38%). Incretin-based therapies significantly increased the
risk for hypoglycemia compared to placebo (n 5 7; relative risk [RR], 1.38; 95% CI, 1.01-1.89; I 2 5 0%)
but no effect was observed versus active comparators (n 5 4; RR, 0.24; 95% CI, 0.03-1.94; I 2 5 52%).
Limited evidence exists for all-cause mortality (placebo: n 5 7 [RR, 1.21; 95% CI, 0.64-2.29; I 2 5 0%];
active comparators: n 5 3 [RR, 0.70; 95% CI, 0.32-1.54; I 2 5 0%]).
Limitations: Variation among interventions, small number of studies, heterogeneity between studies, and
high risk for attrition bias in 7 of the selected studies.
Conclusions: In patients with moderate or severe CKD, incretin-based therapies are effective in reducing
HbA1c levels. Hypoglycemic events are rare, and wide CIs for the association preclude any definitive
conclusions. Likewise, wide CIs were observed for mortality, cardiovascular events, and end-stage renal
disease.
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hemoglobin (HbA1c); hyperglycemia.Diabetes is the top cause of chronic kidney dis-ease (CKD) and as the rate of diabetes
increases, CKD and associated cardiovascular out-
comes are a growing public health concern.1,2 Dia-
betes itself, and in combination with CKD, is
associated with increased rates of cardiovascular dis-
ease and cardiovascular-related death, emphasizing1Faculty of Medicine and 2School of Pharmacy,
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y Dis. 2016;68(5):733-742the importance of appropriate treatment for patients in
this population.3,4 Increased albuminuria and reduced
kidney function, as measured by glomerular ﬁltration
rate (GFR), are both independent risk factors for
cardiovascular events and other adverse effects.5,6
Although many antidiabetic therapies are available
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Howse et aldiabetes mellitus, the pharmacokinetics and pharma-
codynamics of these medications are often altered in
the context of CKD.7
Incretin-based therapies are a novel class of anti-
diabetic medications increasingly used in the treat-
ment of hyperglycemia in patients with type 2
diabetes.8 The Canadian Diabetes Association (CDA)
2013 clinical practice guidelines, a position statement
of the American Diabetes Association and the Euro-
pean Association for the Study of Diabetes
(ADA-EASD), and a consensus statement by the
American Association of Clinical Endocrinologists
and American College of Endocrinology (ACCE/
ACE) recommend incretin-based therapies, dipeptidyl
peptidase 4 (DPP-4) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists, as an option
for add-on therapy to ﬁrst-line therapy with metfor-
min or other antidiabetic medications.3,9,10 However,
there is limited evidence about the relative clinical
effectiveness and safety of incretin-based therapies in
patients with diabetes and CKD.
Other reviews have found that incretin-based
therapies, particularly DPP-4 inhibitors, are effective
and comparable alternatives to metformin and other
oral antidiabetic medications for blood glucose
management and are tolerable in patients with type 2
diabetes and CKD with appropriate dose adjust-
ment.11-15 One study’s pooled analysis of linagliptin
found that dose adjustment was not necessary in
patients with type 2 diabetes and reduced kidney
function.13 However, there are limited studies that
focus on incretin-based therapies in patients with
moderate to severe CKD (stages 3, 4, or 5), and
previous reviews of this patient population have not
included a meta-analysis.8,11,12,15 We aimed to
conduct a systematic review and meta-analysis of
randomized controlled trials to assess the safety and
efﬁcacy of incretin-based therapies in patients with
type 2 diabetes and moderate or severe CKD.
METHODS
Literature Search
Database searches included The Cochrane Library, PubMed,
Embase, and International Pharmaceutical Abstracts from incep-
tion to March 9, 2016. The articles were not restricted based on
language or publication status. Studies were limited to randomized
controlled trials using a tested highly sensitive search strategy for
each database.16 Alternative sources searched for published and
unpublished trials included the reference lists of the CDA and
National Kidney Foundation clinical practice guideline docu-
ments, clinical trial registries, and the references of associated
systematic reviews and meta-analyses.
Both Medical Subject Headings and keyword searches were
performed in The Cochrane Library and PubMed. Emtree and
keyword searches were completed in Embase and keyword
searches were conducted in International Pharmaceutical Abstracts.
The search terms included “kidney disease,” “renal impairment,”
“incretin,” “dipeptidyl-peptidase 4,” and “glucagon-like peptide7341,” which were adjusted according to the requirements of each
database. A sample search strategy is provided in Item S1 (pro-
vided as online supplementary material).
Review Methods and Selection Criteria
Eligible trials were listed and assessed independently by 2
reviewers (P.M.H. and L.N.C.) using predeﬁned inclusion criteria.
Studies were included if they met the following criteria: (1) ran-
domized controlled design; (2) patients with type 2 diabetes; (3)
patients 18 years or older; (4) patients with moderate CKD, severe
CKD, or end-stage renal disease (ESRD), as deﬁned by the indi-
vidual study; (5) the intervention group received either a DPP-4
inhibitor or GLP-1 receptor agonist; (6) the comparison group
received placebo or an active comparator, the later deﬁned as an
antidiabetic medication other than an incretin-based therapy; and
(7) reported at least one outcome of interest. There were no
restrictions on length of follow-up. In the case of multiple publi-
cations from the same population, we included the report with the
longer follow-up.17,18
Outcomes of Interest
Outcome measures included change in glycated hemoglobin
(HbA1c) level (as a percentage) as the primary measure of efﬁcacy,
and the proportion of patients having a hypoglycemic event as the
primary measure of safety. Secondary outcomes included change
in fasting plasma glucose level (millimoles per liter), all-cause
mortality, acute myocardial infarction, stroke, ESRD/kidney
transplantation/dialysis, and major adverse cardiovascular
events.19 Major adverse cardiac event was deﬁned as a composite
outcome of cardiovascular death, nonfatal myocardial infarction,
and nonfatal stroke.20,21
Data Extraction
Two authors (P.M.H. and L.N.C.) used predeﬁned forms to
extract data from the studies, including study and design charac-
teristics, number of participants, participant baseline characteris-
tics (eg, age, sex, and duration of diabetes), follow-up period,
intervention and comparison particulars (eg, drug and dose), and
outcomes (eg, HbA1c level and adverse events). HbA1c level did
not have to be the primary outcome and could have been reported
as either pre- and postintervention values or change in HbA1c level
from baseline to end point. The quality of each study was inde-
pendently assessed by 2 authors (P.M.H. and L.N.C.) using the
Cochrane Collaboration’s risk-of-bias assessment tool.22 In the
case of any disagreement, a third author (J.-M.G.) also assessed
the study.
Statistical Analyses
For each outcome measure of interest, random-effects meta-
analyses were conducted to pool mean differences for continuous
outcomes and relative risks (RRs) for dichotomous outcomes in
order to determine the effect of DPP-4 inhibitors or GLP-1
receptor agonists versus placebo and active comparator. The
random-effects model was used to account for statistical
heterogeneity, particularly because the intervention particulars
(eg, drug, dose, and frequency) varied among studies.22,23 We
used a restricted likelihood estimation approach to calculate 95%
conﬁdence intervals (CIs).24 For dichotomous outcomes, we used
an exact binomial likelihood estimator to calculate the variance.
For groups with zero events, we added 0.5 to each cell.22 Forest
plots were used to display the mean difference or RR and 95% CI
for each study and the pooled summary treatment effect. The I2
statistic was used to measure heterogeneity across studies.22,25
Heterogeneity was explored through subgroup analyses whereby
results were stratiﬁed by type of incretin-based therapy,
CKD stage, and risk of bias. All data analyses were performed
using R statistical software, version 3.3.0 (R Foundation forAm J Kidney Dis. 2016;68(5):733-742
Incretin-Based Therapies in CKDStatistical Computing, Vienna, Austria). The study protocol is
available as Item S2.
RESULTS
Included Studies
A detailed summary of the identiﬁcation and
selection of studies is provided in Fig 1. Through our
comprehensive search, we identiﬁed 1,619 unique
citation records fromwhich 13 studies were selected for
inclusion in the meta-analysis.26-38 Only 11 of the 13
were full-length articles and subsequently included in
the risk-of-bias assessment.26-32,34-37 Authors of the
full-length articles were contacted for additional
outcome data; however, only one reply was received.37
Characteristics of the 13 studies included in this review
are presented in Table 1. Study-level patient character-
istics can be found in Table S1. Study interventions
included DPP-4 inhibitors (sitagliptin, vildagliptin,
linagliptin, saxagliptin, alogliptin, and gemigliptin) and
GLP-1 receptor agonists (albiglutide and liraglutide).
Most studies used placebo comparators28-38 and those
with active comparators26,27,29,33 were sulfonylureas
(glipizide or glimepiride). None of the studies included
metformin as a comparator due to the contraindication
for creatinine clearances, 60 mL/min/1.73 m2 despiteRecords identified 
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Figure 1. Study flow diagram. Abbreviation: KDO
Am J Kidney Dis. 2016;68(5):733-742the perception among some that these guidelinesmaybe
overly restrictive.9 Two of the studies started the trial
with a placebo comparator and switched to a sulfonyl-
urea at week 12.29,33 Eleven of the included studies
reported a change in HbA1c level
26-35,38 and 10 reported
hypoglycemia,26,27,29-36 although deﬁnitions of hypo-
glycemia differed among studies (Table S2). All 11
full-text studies reported baseline demographic and
anthropometric traits to be generally well balanced be-
tween groups.26-32,34-37 Each study reported that par-
ticipants were to continue their background antidiabetic
therapy while participating in the study.
Risk-of-Bias Assessment
A summary of study quality is presented in Fig 2.
In accordance with the Cochrane Collaboration’s tool
for assessing risk of bias,22 an overall “high risk of
bias” classiﬁcation was given to studies that had been
scored as high risk for 1 or more of the 6 domains.
High risk of bias indicates possible bias that weakens
conﬁdence in the results. An overall “low risk of bias”
classiﬁcation was assigned to studies that had been
scored as low risk for all key domains, indicating that
any possible bias is unlikely to alter results. For a
domain to be classiﬁed as “unclear risk of bias,” there identified 
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Table 1. Characteristics of Trials Included in the Present Analysis
Study N Follow-up, wk Interventiona Comparatora HbA1c FPG Hypo
b Death MI Stroke MACEb ESRD
Arjona
Ferreira et al26
(2013)
129 54 Sitagliptin 25 mg
13/d
Glipizide,
initiated at
2.5 mg 13/d,
titrated to max
of 10 mg, 23/d
X X X X X
Arjona
Ferreira et al27
(2013)
423 54 Sitagliptin: 50 mg/
d (two 25-mg
tablets) for
eGFR , 60;
25 mg/d (one
25-mg tablet) for
eGFR , 30
Glipizide starting
with dose of
2.5 mg/d,
titrated to max
of 20 mg/d
X X X X X
Barnett et al28
(2013)
65c 24 Linagliptin 5 mg/d Placebo X
Chan et al29
(2008)
91 52 Sitagliptin: 50 mg/
d for eGFR , 60;
25 mg/d for
eGFR , 30
Placebo,
switched to
glipizide wk 12
X X X X X
Davies et al30
(2016)
279 26 Liraglutide 1.8 mg
initiated at
0.6 mg/d and
increased by
0.6 mg/d each wk
Placebo X X X X X
Idorn et al31
(2016)
47 12 Liraglutide, titrated
dose of 0.6, 1.2,
or 1.8 mg
Placebo X X X
Kothny et al32
(2012)
525 52 Vildagliptin 50 mg/d Placebo X X X
Laakso et al33
(2013)
235 52 Linagliptin 5 mg
13/d
Placebo,
switched to
glimepiride
(1-4 mg/d)
wk 12
X X X X X X X
McGill et al34
(2013)
133 52 Linagliptin 5 mg/d Placebo X X X X X X X
Nowicki et al35
(2011)
170 52 Saxagliptin 2.5 mg Placebo X X X X X X
Scirica et al36
(2014) and
Udell et al48
(2015)
2,576c 109 (median) Saxagliptin 2.5
mg/d
Placebo X X X X X
White et al37,49
(2013)
1,585c 72 (median) Alogliptin: 12.5 mg
for eGFR , 60;
6.25 mg for
eGFR , 30
Placebo X
Yoon et al38
(2015)
132 12 Gemigliptin 50 mg Placebo X
Abbreviations and definitions: Death, all-cause mortality; eGFR, estimated glomerular filtration rate (in mL/min/1.73 m2); ESRD, end-
stage renal disease; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; Hypo, hypoglycemia; MACE, major adverse car-
diovascular event; max, maximum; MI, myocardial infarction.
aAll treatments and comparators were in addition to antihyperglycemic background therapy.
bOutcome definitions are provided in the supplementary material (Table S2).
cSubgroup.
Howse et almust have been insufﬁcient information to allow
judgment of either low risk or high risk. Nine
studies reported adequate random sequence genera-
tion,26-31,35-37 whereas only 6 reported adequate
allocation concealment.28,30,31,35-37 All studies re-
ported blinding of participants and personnel. Risk of
attrition bias (incomplete outcome data) was detected736in 7 of the selected studies, earning the status of high
risk.26,27,29,31,32,34,35 Funnel plots were constructed
for primary outcomes; however, there was an
inadequate number of included studies (,10) for
either outcome to properly assess publication bias
through a funnel plot or use other tests (eg, Egger
regression test).39 Therefore, publication bias cannotAm J Kidney Dis. 2016;68(5):733-742
Figure 2. Risk-of-bias summary.
Incretin-Based Therapies in CKDbe excluded as a factor affecting the results of this
meta-analysis.
Quantitative Analysis
Thirteen studies that included a total of 6,848 patients
with data for at least 1 outcome were included in the
meta-analysis (Table 1).26-38 Eleven studies used a
DPP-4 inhibitor as the intervention drug,26-29,32-38 9 of
which were compared to placebo.28,29,32-38 Two studies
used GLP-1 receptor agonists as the intervention, both
of which were compared to placebo.30,31 Chan et al29
and Laakso et al33 started their trials with a placebo
comparator and switched to glipizide and glimepiride,
respectively, at week 12. In our analysis, we included
these studies with the DPP-4 inhibitor versus placebo
group using the 12-week end point values and with
the DPP-4 inhibitor versus sulfonylurea group using
the 52-week end point values.
Primary Outcomes
Eleven studies reported change in HbA1c level
from baseline.26-35,38 The pooled mean difference of
change in HbA1c level from baseline was signiﬁcantly
greater in the incretin-based group versus placeboAm J Kidney Dis. 2016;68(5):733-742group (weighted mean difference [WMD], 20.64%;
95% CI, 20.79 to 20.48; P , 0.001; I2 5 43%). In
contrast, there was no difference for the change in
HbA1c level when DPP-4 inhibitors were compared to
sulfonylurea (WMD, 20.07; 95% CI, 20.25 to 0.12;
P 5 0.5; I2 5 38%; Fig 3).
The pooled RR of hypoglycemic events indicated a
statistically signiﬁcant risk for the incretin versus
placebo group (RR, 1.38; 95% CI, 1.01-1.89;
P 5 0.05), but no effect in the incretin versus sulfo-
nylurea group (RR, 0.24; 95% CI, 0.03-1.94; P5 0.2).
The incretin versus placebo analyses for hypoglycemia
exhibited no heterogeneity (I2 5 0%), whereas the
incretin versus sulfonylurea analysis exhibited mod-
erate heterogeneity (I2 5 52%). One study31 reported
no incidents of hypoglycemia in either group. Chan
et al29 and Laakso et al33 were included in the incretin
versus sulfonylurea analysis for hypoglycemic events
because the outcome was only reported following the
comparator switch at the 52-week end point.
Secondary Outcomes
The pooled mean difference of the change in fast-
ing plasma glucose levels between the treatment and
comparison groups was found to be signiﬁcant in the
incretin versus placebo analysis (WMD, 20.61 [95%
CI, 21.16 to 20.06] mmol/L; P 5 0.03; I2 5 43%),
favoring incretins. In contrast, there was no difference
for change in fasting plasma glucose levels in the
incretin versus sulfonylurea analysis (WMD, 0.28
[95% CI, 20.12 to 0.68] mmol/L; P 5 0.2; I2 5 0%),
favoring the active comparator (Table 2).
The pooled RR for all-cause mortality indicated no
evidence of effect in either the incretin versus placebo
group (RR, 1.21; 95%CI, 0.64-2.29; P5 0.6; I25 0%)
or the incretin versus sulfonylurea group (RR, 0.70;
95%CI, 0.32-1.54; P5 0.4; I25 0%). Chan et al29 was
included in the incretin versus placebo incretin analysis
using the 12-week values and in the incretin versus
sulfonylurea analysis using the 52-week values. The
pooled RR for the ESRD, dialysis, or transplantation
outcome indicated no evidence of effect in the incretin
versus placebo analysis (RR, 1.07; 95% CI, 0.78-1.47;
P 5 0.7; I2 5 0%); however, only 2 studies35,36 re-
ported this outcome. No studies in the incretin versus
sulfonylurea group reported the outcome.
Nine studies were included in the pooled RR for
myocardial infarctions: 6 for incretin versus pla-
cebo29,30,33-36 (RR, 1.23; 95% CI, 0.88-1.73; P 5 0.2;
I2 5 0%) and 3 in the incretin versus sulfonylurea
analysis26,27,33 (RR, 1.02; 95% CI, 0.21-5.07; P5 0.9;
I25 0%). Stroke was only reported as an outcome in 3
studies33,34,36 and major adverse cardiac event was re-
ported as an outcome in 433,34,36,37 of the 13 studies.
Forest plots for secondary outcomes are illustrated in
ﬁgures a-f of Item S3.737
Figure 3. Forest plots for relative
treatment effect of incretins versus pla-
cebo and active comparators for primary
outcomes: (A) Change in glycated hemo-
globin (HbA1c) level (percent) for incretin
versus placebo, (B) change in HbA1c level
for incretin versus active comparator, (C)
hypoglycemia for incretin versus placebo,
and (D) hypoglycemia for incretin versus
active comparator. Weights are from
random effects (RE) analysis. Abbrevia-
tions: CI, confidence interval; DPP-4,
dipeptidyl peptidase 4; GLP-1, glucagon-
like peptide 1.
738 Am J Kidney Dis. 2016;68(5):733-742
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Table 2. Summary of Results for Secondary Analyses
Comparison No. of Events No. of Patients
Effect Size
(95% CI) I2 No. of Studies
Change in FPG from baseline
Incretin vs placebo WMD NA 828 20.61 (21.16 to 20.06) 43% 5
Incretin vs active comparator WMD NA 677 0.28 (20.12 to 0.68) 0% 4
All-cause mortality
Incretin vs placebo RR 40 1,439 1.21 (0.64 to 2.29) 0% 7
Incretin vs active comparator RR 26 642 0.70 (0.32 to 1.54) 0% 3
Stroke
Incretin vs placebo RR 54 2,944 0.99 (0.58 to 1.69) 0% 3
Incretin vs active comparator NA NA NA NA 0
Myocardial infarction
Incretin vs placebo RR 136 3,482 1.23 (0.88 to 1.73) 0% 6
Incretin vs active comparator RR 4 786 1.02 (0.21 to 5.07) 0% 3
MACE
Incretin vs placebo RR 553 4,509 1.02 (0.86 to 1.20) 0% 4
Incretin vs active comparator NA NA NA NA 0
ESRD/dialysis/transplantation
Incretin vs placebo RR 154 2,746 1.07 (0.78 to 1/47) 0% 2
Incretin vs active comparator NA NA NA NA 0
Note: Values in parentheses for effect size are 95% CI.
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; FPG, fasting plasma glucose; MACE, major adverse
cardiovascular event; NA, not applicable; RR, relative risk; WMD, weighted mean difference.
Incretin-Based Therapies in CKDSubgroup Analyses
A subgroup analysis was conducted using the risk-of-
bias categories. Results for mean change in HbA1c level
were found to be consistent across risk-of-bias cate-
gories. Results for hypoglycemia when incretins were
compared to placebo gave signiﬁcant evidence of effect
for low-risk studies (RR, 1.54; 95% CI, 1.07-2.22; P 5
0.02; I2 5 0%) but no evidence of effect for high-risk
studies (RR, 0.93; 95% CI, 0.38-2.27; P 5 0.9; I2 5
18%). Results for hypoglycemia when incretins were
comparedwith sulfonylureaswere found to be consistent
with those when all studies were combined (Fig S1).
A subgroup analysis comparing study data based
on patient CKD stage was also conducted. When
incretins were compared to placebo for mean
change in HbA1c level, results were found to be
consistent with the overall results, signiﬁcant evi-
dence of effect, for all CKD stages except the
ESRD group (stage 5). These results for incretins
versus active comparator for mean change in HbA1c
level were found to be consistent with those when
CKD stages were combined, as provided in each
individual study. Results for hypoglycemia when
incretins were compared with placebo gave signif-
icant evidence of effect for the CKD stage 3 group,
but showed no evidence of effect for the other
CKD stages. Results for hypoglycemia when
incretins were compared to active comparator wereAm J Kidney Dis. 2016;68(5):733-742found to be consistent with those when all studies
were combined (Fig S2).
DISCUSSION
Results of this systematic review and meta-analysis
of 13 randomized controlled trials indicate that
incretin-based therapies are effective in reducing
HbA1c levels compared to placebo in patients with
estimated GFRs (eGFRs) , 60 mL/min/1.73 m2.
Importantly, we found that neither DPP-4 inhibitors
nor GLP-1 receptor agonists were associated with
hypoglycemia compared to placebo or active
comparator; however, there was a minimal increased
risk for hypoglycemia when incretin-based agents
were combined versus placebo. Furthermore, our
ﬁndings regarding all-cause mortality, ESRD, and
cardiovascular events are limited given the lack of
events, short follow-up of included studies, and lack
of formal adjudication of cardiovascular events within
all studies.
Our analysis provides more precise evidence than
previous studies11,12,15 that incretin-based therapies
are effective in reducing glycemia without substan-
tially increasing the risk for hypoglycemia within a
subgroup of patients with eGFRs , 60 mL/min/
1.73 m2. Ramirez et al11 conducted a review to
evaluate the use of DPP-4 inhibitors in patients with
type 2 diabetes and CKD. However, the review only739
Howse et alincluded 6 studies of patients with eGFRs , 60 mL/
min/1.73 m2 and the results were not pooled.11
Davis12 conducted a systematic review to determine
the efﬁcacy, tolerability, and safety of DPP-4
inhibitors in patients with type 2 diabetes and
reduced kidney function. The study indicated that
DPP-4 inhibitors could be used, and were well
tolerated, in patients with type 2 diabetes and reduced
kidney function and were comparable to other oral
therapies in terms of glycemic efﬁcacy. Davis stated
there was no clear indication of safety (renal toxicity
and hypoglycemia) from the included long-term
efﬁcacy studies of people with CKD and suggested
that dose adjustment of DPP-4 inhibitors is recom-
mended in this subgroup to avoid drug accumula-
tion.12 Cooper et al40 conducted a pooled analysis of
large clinical trials to investigate the renal safety of
linagliptin in patients with type 2 diabetes. Their
study found that linagliptin was not associated with
increased risk for kidney disease; however, it did not
assess other safety measures, such as hypoglycemia or
cardiovascular events. Our meta-analysis expands on
these studies by evaluating cardiovascular outcomes
in this clinically important subgroup of patients,
which has not been previously reported.
Important questions remain regarding the safety of
incretin-based therapies in terms of cardiovascular
events in patients with CKD. The Saxagliptin
Assessment of Vascular Outcomes Recorded in
Patients With Diabetes Mellitus–Thrombolysis in
Myocardial Infarction (SAVOR TIMI) 5336 and
Exploring the Cardiovascular Safety of Therapies for
Type 2 Diabetes (EXAMINE)37 trials included in this
study reported CKD subgroups for cardiovascular
outcomes; however, patient-level data were unavai-
lable for all outcomes. Additional data from other
ongoing trials should present a more speciﬁc assess-
ment of the risks of cardiovascular outcomes,
particularly in patients with CKD. The Cardiovascular
Outcome Study of Linagliptin Versus Glimepiride in
Patients With Type 2 Diabetes (CAROLINA)41 is an
ongoing trial comparing linagliptin and glimepiride
with respect to cardiovascular outcomes in patients
with type 2 diabetes. Given that change in eGFR from
baseline is reported as a secondary outcome, special
patient groups, such as those with CKD, may be
reported in this and other trials, providing additional
data for future meta-analyses.
Although to our knowledge our review is the most
comprehensive meta-analyses to date regarding the
safety and efﬁcacy of incretin-based therapies aimed
at patients with CKD, there are limitations that
should be considered when interpreting the results.
First, there was variation among studies in the
intervention drug used. Although the effective
dosage, metabolism, and excretion differ among740incretin therapies, they are understood to be similar
in terms of their efﬁcacy in HbA1c level reduction
and safety and tolerability proﬁles.42-46 Dose
adjustments are not required for patients with CKD
taking linagliptin or albiglutide.3,47 However, studies
with shorter follow-up may favor agents with less
glycemic durability. Additionally, the relatively
small number of studies available limited our ability
to account for between-study variation, particularly
in the incretin versus active comparator group. The
wide CIs for effects on hypoglycemia and mortality
prevent us from making deﬁnition conclusions.
Although 2 abstracts that contained sufﬁcient re-
sults were included in this meta-analysis,33,38 a
number of studies were identiﬁed in our search that
met the primary inclusion criteria, but were elimi-
nated during the screening process due to limited
availability of results (eg, abstracts without out-
comes of interest and trials in progress without
published results). As results of these studies
become available and further research is conducted
on the use of incretins in patients with CKD, an
updated meta-analysis could provide additional
power. There was considerable heterogeneity be-
tween the studies included in some of the analyses,
particularly those comparing incretins and other
antidiabetic therapies (sulfonylureas). Although the
different antidiabetic therapies may explain this
heterogeneity, there were not enough studies to
conduct informative subgroup analyses or metare-
gression based on different active comparators.
Seven of the included studies were given a grade of
high risk for attrition bias (incomplete outcome
data). This was largely due to the lack of infor-
mation provided by authors on the amount or
imbalance of missing data and how it was handled
in the analysis. This meta-analysis carries a risk of
reporting bias because not all studies reported each
outcome of interest. Although a number of studies
had registered protocols, most reported on our
primary outcomes while very few reported the
cardiovascular outcomes. Finally, we were unable
to completely separate all studies into explicit
groups based on CKD stage, which may have
provided valuable information regarding differences
in the safety and efﬁcacy of incretins among pa-
tients with a moderate versus severe decrease in
kidney function. However, a subgroup analysis was
conducted based on the information available.
This systematic review and meta-analysis focused
on the safety and efﬁcacy of incretin-based therapies
as antidiabetic agents when compared to placebo or
active comparators in patients with moderate or se-
vere reduction in kidney function. Our meta-analysis
conﬁrms several clinically relevant effects of the
incretin-based therapies, including effective reductionAm J Kidney Dis. 2016;68(5):733-742
Incretin-Based Therapies in CKDof glycemia without a substantial increased risk for
hypoglycemia within a clinically important subgroup
of patients. However, given the wide CIs for effects
on hypoglycemia and mortality, we are unable to
preclude deﬁnition conclusions. Uncertainty still ex-
ists regarding the effects of DPP-4 inhibitors and
GLP-1 receptor agonists on the risk for all-cause
mortality and other long-term outcomes, including
cardiovascular disease and ESRD. Despite the num-
ber of studies published, more data are needed to
precisely quantify associations with all-cause mor-
tality, cardiovascular events, and ESRD. Future
collaborative meta-analyses, particularly those that
incorporate subgroup analysis based on CKD stage or
patient-level analysis, would help further characterize
the safety and efﬁcacy of incretin-based therapies in
patients with type 2 diabetes and CKD.
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